SCHEMBL3675362

SCHEMBL3675362

O=C(O)[C@H]1CC(CO)CN1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ARG1 P05089 2/20 0.59
CYP1A2 P05177 3/20 0.54
ALOX15 P16050 3/20 0.54
CYP2C19 P33261 3/20 0.54
CYP2D6 P10635 3/20 0.54
SLC1A3 P43003 1/20 0.54
SLC1A2 P43004 1/20 0.54
SLC1A1 P43005 1/20 0.54
DPP4 P27487 1/20 0.45
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
THRB P10828 2/20 0.44
ALDH1A1 P00352 1/20 0.44
GRIN2D O15399 1/20 0.44
GRIN3B O60391 1/20 0.44
GRIA1 P42261 1/20 0.44
GRIA2 P42262 1/20 0.44
GRIA3 P42263 1/20 0.44
GRIA4 P48058 1/20 0.44
GRIN1 Q05586 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1476315 1.00 ARG1 (0.59) ARG1CYP1A2ALOX15CYP2C19CYP2D6
SCHEMBL4302105 1.00 ARG1 (0.59) ARG1CYP1A2ALOX15CYP2C19CYP2D6
SCHEMBL3675363 1.00 ARG1 (0.59) ARG1CYP1A2ALOX15CYP2C19CYP2D6
SCHEMBL3676541 1.00 ARG1 (0.59) ARG1CYP1A2ALOX15CYP2C19CYP2D6
SCHEMBL1512874 1.00 ARG1 (0.59) ARG1CYP1A2ALOX15CYP2C19CYP2D6
SCHEMBL1512877 1.00 ARG1 (0.59) ARG1CYP1A2ALOX15CYP2C19CYP2D6
Hydrochloric Acid SCHEMBL1914280 0.98 ARG1 (0.58) ARG1CYP1A2ALOX15CYP2C19CYP2D6
SCHEMBL7537502 0.82 ARG1 (0.44) ARG1CYP1A2ALOX15CYP2C19CYP2D6
SCHEMBL7694066 0.81 ARG1 (0.44) ARG1CYP1A2ALOX15CYP2C19CYP2D6
SCHEMBL4950542 0.81 ARG1 (0.58) ARG1CYP1A2ALOX15CYP2C19CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250295157-A1 METHODS FOR THE IMPROVEMENT AND MAINTENANCE OF WEIGHT LOSS SOCIETE DES PRODUITS NESTLE S.A. (CH) 2025-09-25 US disclosed
US-12349713-B2 Methods for the improvement and maintenance of weight loss SOCIETE DES PRODUITS NESTLE S.A. (CH) 2025-07-08 US disclosed
EP-4099849-A1 COMPOSITIONS AND METHODS FOR THE IMPROVEMENT AND MAINTENANCE OF GLUCOSE METABOLISM IN CHILDHOOD AND ADOLESCENCE Société des Produits Nestlé S.A. (CH) 2022-12-14 EP disclosed
US-20220369685-A1 COMPOSITIONS AND METHODS FOR THE IMPROVEMENT AND MAINTENANCE OF GLUCOSE METABOLISM IN CHILDHOOD AND ADOLESCENCE NESTLE SA (CH) 2022-11-24 US disclosed
US-20220338521-A1 COMPOSITIONS AND METHODS FOR THE IMPROVEMENT AND MAINTENANCE OF WEIGHT LOSS SOCIETE DES PRODUITS NESTLE S.A. (CH) 2022-10-27 US disclosed
CN-114980753-A Compositions and methods for improving and maintaining glucose metabolism in children and adolescents 雀巢产品有限公司 2022-08-30 CN disclosed
CN-114423304-A Compositions and methods for improvement and maintenance of weight loss 雀巢产品有限公司 2022-04-29 CN disclosed
WO-2021156181-A1 COMPOSITIONS AND METHODS FOR THE IMPROVEMENT AND MAINTENANCE OF GLUCOSE METABOLISM IN CHILDHOOD AND ADOLESCENCE Société des Produits Nestlé S.A. (CH) 2021-08-12 WO disclosed
EP-3197445-B1 PROLINE OR PROLINE DERIVATIVES FOR THE TREATMENT OF DEMENTIA SALAMA ZOSER B (DE) 2021-04-28 EP disclosed
WO-2021058358-A1 COMPOSITIONS AND METHODS FOR THE IMPROVEMENT AND MAINTENANCE OF WEIGHT LOSS Société des Produits Nestlé S.A. (CH) 2021-04-01 WO disclosed
US-10328051-B2 Proline or proline derivatives for the treatment of dementia SALAMA ZOSER B (DE) 2019-06-25 US disclosed
US-20170239215-A1 PROLINE OR PROLINE DERIVATIVES FOR THE TREATMENT OF DEMENTIA SALAMA ZOSER B (DE) 2017-08-24 US disclosed
EP-3197445-A1 PROLINE OR PROLINE DERIVATIVES FOR THE TREATMENT OF DEMENTIA Salama, Zoser B. (DE) 2017-08-02 EP disclosed
WO-2016046162-A1 PROLINE OR PROLINE DERIVATIVES FOR THE TREATMENT OF DEMENTIA SALAMA ZOSER B (DE) 2016-03-31 WO disclosed
US-7727530-B2 Anti-cancer composition comprising proline or its derivatives and an anti-tumour antibody SALAMA ZOSER B 2010-06-01 US disclosed
EP-1765328-A1 ANTI-CANCER COMPOSITION COMPRISING PROLINE OR ITS DERIVATIVES AND AN ANTI-TUMOUR ANTIBODY Salama, Zoser B. (DE) 2007-03-28 EP disclosed
WO-2005120495-A1 ANTI-CANCER COMPOSITION COMPRISING PROLINE OR ITS DERIVATIVES AND AN ANTI-TUMOUR ANTIBODY SALAMA ZOSER B (DE) 2005-12-22 WO disclosed
US-20050276810-A1 Anti-cancer composition comprising proline or its derivatives and an anti-tumour antibody SALAMA ZOSER B 2005-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10328051-B2 Proline or proline derivatives for the treatment of dementia PSEN2, PSEN1, PRNP ARG1 154/4885CYP1A2 2826/4885ALOX15 2262/4885
US-20170239215-A1 PROLINE OR PROLINE DERIVATIVES FOR THE TREATMENT OF DEMENTIA PSEN2, PSEN1, PRNP ARG1 154/4885CYP1A2 2826/4885ALOX15 2262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.